MetaCap

Nephros (NEPH) vs InspireMD (NSPR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nephros (NEPH) has outperformed InspireMD (NSPR) over the past year, losing 46.4% versus a loss of 72.0%. Over five years, NEPH leads with a -63.6% price change compared with -85.1% for NSPR. InspireMD is the larger company by market cap ($29.2 million vs $28.4 million), about 1.0 times the size, while Nephros is growing revenue faster (+32.7% vs +28.1%).

Nephros converts more of its revenue into profit, with a net margin of 6.4% versus -543.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NEPH-46.41%NSPR-72.02%
+24%-29%-82%
Nov 21, 20251 yearNov 20, 2026
NEPH-64.82%NSPR-85.52%
+4%-44%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NEPH versus NSPR key metrics
MetricNEPHNSPR
Share price$2.61$0.54
Market cap$28.37M$29.23M
1-day change-8.10%-12.97%
YTD return-46.52%-69.66%
1-year return-46.41%-72.02%
5-year return-63.60%-85.12%
P/E ratio (TTM)15.35—
Forward P/E11.86—
EPS (TTM)$0.17$-0.57
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$18.79M$8.98M
Revenue growth (YoY)+32.67%+28.11%
Net income (latest FY)$1.19M$-48.79M
Gross margin61.87%29.50%
Operating margin6.10%-552.56%
Net margin6.35%-543.33%
52-week high$6.42$2.17
52-week low$2.61$0.43
Distance from 52-week high-59.35%-75.12%
Analyst consensusnonenone
Avg. price target upside+139.46%+516.67%
Average volume48.33K234.68K
Shares outstanding10.87M54.13M
Employees36127
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NEPH has outperformed NSPR by 25.6 percentage points over the past year.
  • Nephros is more profitable, keeping 6.4 cents of every revenue dollar as net income versus -543.3 cents for InspireMD.

About Nephros

NEPH stock →

Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.

Health Care · Medical/Dental Instruments · 36 employees

About InspireMD

NSPR stock →

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions.

Health Care · Medical/Dental Instruments · 127 employees

NEPH vs NSPR FAQ

Which is bigger, Nephros or InspireMD?

InspireMD (NSPR) is larger, with a market capitalization of $29.23M compared with $28.37M for Nephros (NEPH).

Which stock has performed better over the past year, NEPH or NSPR?

NEPH returned -46.41% over the past 12 months, compared with -72.02% for NSPR (price return, excluding dividends). Past performance does not predict future results.

Are Nephros and InspireMD in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons